Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms

Journal of Interferon and Cytokine Research

Volumn 33, Issue 4, 2013, Pages 145-153

  Stein, Brady L ^a   Tiu, Ramon V ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BETA INTERFERON; CASPASE 4; CASPASE 8; HYDROXYUREA; INTERFERON; JANUS KINASE 2; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLEEDING; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL CULTURE; CELL PROLIFERATION; CELLULAR IMMUNITY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG WITHDRAWAL; ERYTHROCYTOSIS; ERYTHROID CELL; FATIGUE; FIBROBLAST; FLU LIKE SYNDROME; GENE EXPRESSION REGULATION; GENE MUTATION; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; LEUKOCYTOSIS; LIVER FUNCTION TEST; MEGAKARYOPOIESIS; MYALGIA; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NEUTROPENIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROIDITIS; TUMOR IMMUNITY;

ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON-ALPHA; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; POLYETHYLENE GLYCOLS; PRIMARY MYELOFIBROSIS; RECOMBINANT PROTEINS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPOIESIS;

EID: 84876138022     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0120     Document Type: Review

References (45)

1. Alvarado Y, Cortes J, et al. 2003. Pilot study of pegylated interferon- alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 51(1):81-86.
2. Balkwill F, Taylor-Papadimitriou J. 1978. Interferon affects both G1 and S + G2 in cells stimulated from quiescence to growth. Nature 274(5673):798-800.
3. Barbui T, Barosi G, et al. 2011. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761-770.
4. Bellucci S, Harousseau JL, et al. 1988. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 2(8617):960- 961.
5. Carlo-Stella C, Cazzola M, et al. 1987. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 70(4):1014-1019.
6. Chawla-Sarkar M, Lindner DJ, et al. 2003. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3):237-249.
7. Dai CH, Price JO, et al. 1998. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 91(4):1235-1242.
8. Eickelberg O, Pansky A, et al. 2001. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J 15(3):797-806.
9. Feng GS, Chong K, et al. 1992. Identification of double-stranded RNA-binding domains in the interferon-induced doublestranded RNA-activated p68 kinase. Proc Natl Acad Sci U S A 89(12):5447-5451.
10. Giles FJ, Singer CR, et al. 1988. Alpha-interferon therapy for essential thrombocythaemia. Lancet 2(8602):70-72.
11. Gowin K, Thapaliya P, et al. 2012. Experience with pegylated Interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 97(10):1570-1573.
12. Guarda G, Braun M, et al. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34(2):213-223.
13. Gugliotta L, Bagnara GP, et al. 1989. In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 71(2):177-181.
14. Gugliotta L, Bulgarelli S, Vianelli N, Russo D, Candoni A, Rupoli S, et al. 2005. PEG intron treatment in 90 patients with essential thrombocythemia (ET) final report of a phase II study. ASH Annual Meeting Abstracts 106(11):2600.
15. Hasselbalch HC. 2011. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 4(6):637-655.
16. Hobeika AC, Etienne W, et al. 1998. IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer 77(1):138-145.
17. Ianotto JC, Kiladjian JJ, et al. 2009. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 146(2):223-225.
18. Iwase S, Furukawa Y, et al. 1997. Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells. J Biol Chem 272(19):12406-12414.
19. Jabbour E, Kantarjian H, et al. 2007. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 110(9):2012-2018.
20. Jewett A, Bonavida B. 1995. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol 15(1):35-44.
21. Kanfer EJ, Price CM, et al. 1993. The in vitro effects of interferongamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with nonleukaemic myeloproliferative disorders. Eur J Haematol 50(5):250-254.
22. Kiladjian JJ, Cassinat B, et al. 2008. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065-3072.
23. Kiladjian JJ, Mesa RA, et al. 2011. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18):4706-4715.
24. Langer C, Lengfelder E, et al. 2005. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica 90(10):1333-1338.
25. Laughlin M, Islam A, et al. 1988. Effect of alpha-interferon therapy on bone marrow fibrosis in hairy cell leukemia. Blood 72(3):936-939.
26. Linkesch W, Gisslinger H, et al. 1985. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses]. Acta Med Austriaca 12(5):123- 127.
27. Lu M, Zhang W, et al. 2010. Interferon-alpha targets JAK2V617Fpositive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 38(6):472-480.
28. Ludwig H, Cortelezzi A, et al. 1985. Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases. Oncology 42 Suppl 1:19-25.
29. Mamus SW, Beck-Schroeder S, et al. 1985. Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes. J Clin Invest 75(5):1496-1503.
30. Messora C, Bensi L, et al. 1994. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 86(2):402-404.
31. Peschel C, Aulitzky WE, et al. 1996. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment- impact on treatment of myeloproliferative disorders. Leuk Lymphoma 22 Suppl 1:129-134.
32. Quintas-Cardama A, Abdel-Wahab O, Levine RL. 2011. Dynamics of mutant alleles in patients with advanced essential thrombocythemia (ET) or polycythemia (PV) during pegylated interferon-alfa-2A (PEG-IFN-{alpha}-2A; Pegasys) therapy. ASH Annual Meeting Abstracts 118(21):281.
33. Quintas-Cardama A, Kantarjian H, et al. 2009. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27(32):5418-5424.
34. Rizza P, Moretti F, et al. 2010. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43(3):204-209.
35. Sacchi S, Kantarjian H, et al. 1995. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13(9):2401-2407.
36. Samuelsson J, Hasselbalch H, et al. 2006. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106(11):2397-2405.
37. Silver RT. 1988. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 2(8607):403.
38. Silver RT. 2006. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107(3): 451-458.
39. Silver RT, Vandris K, et al. 2011. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117(24):6669-6672.
40. Tiefenbrun N, Melamed D, et al. 1996. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol Cell Biol 16(7):3934-3944.
41. Turlure P, Cambier N, Roussel M. 2011. Complete hematological, molecular and histological remissions without cytoreduct treatment lasting after pegylated-interferon {alpha}-2a (peg- IFN{alpha}-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial. ASH Annual Meeting Abstracts 2011(118):280.
42. Veronese FM, Mero A. 2008. The impact of PEGylation on biological therapies. BioDrugs 22(5):315-329.
43. Wang Q, Miyakawa Y., et al. 2000. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietininduced signaling through induction of SOCS-1. Blood 96(6):2093-2099.
44. Weihua X, Lindner DJ, et al. 1997. The interferon-inducible murine p48 (ISGF3gamma) gene is regulated by protooncogene c-myc. Proc Natl Acad Sci U S A 94(14):7227-7232.
45. Wilhelm M, Bueso-Ramos C, et al. 1998. Effect of interferonalpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia 12(1):65-70.